Mitoconix is exploiting research into neurodegenerative disorders undertaken by professor Daria Mochly-Rosen and her team at Stanford University.
Mitoconix Bio, an Israel-based biopharmaceutical startup that has licensed research from Stanford University, has raised $20m in an oversubscribed series A round led by Remiges Ventures.
Arix Bioscience, OrbiMed, the Dementia Discovery Fund and RMGP Bio-Pharma Investment Fund, which invests in portfolio companies of the FuturRx incubator, also contributed capital.
Mitoconix, founded in 2016 by FutuRx, has obtained an exclusive licence to research conducted by professor Daria Mochly-Rosen and her team at Stanford University. The company is working on…